BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 27114589)

  • 21. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer.
    Sheel ARG; Harrison S; Sarantitis I; Nicholson JA; Hanna T; Grocock C; Raraty M; Ramesh J; Farooq A; Costello E; Jackson R; Chapman M; Smith A; Carter R; Mckay C; Hamady Z; Aithal GP; Mountford R; Ghaneh P; Hammel P; Lerch MM; Halloran C; Pereira SP; Greenhalf W
    Am J Gastroenterol; 2019 Jan; 114(1):155-164. PubMed ID: 30353057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance.
    Kluijt I; Cats A; Fockens P; Nio Y; Gouma DJ; Bruno MJ
    J Clin Gastroenterol; 2009 Oct; 43(9):853-7. PubMed ID: 19417680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
    Aslanian HR; Lee JH; Canto MI
    Gastroenterology; 2020 Jul; 159(1):358-362. PubMed ID: 32416142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.
    Kamata K; Kitano M; Kudo M; Sakamoto H; Kadosaka K; Miyata T; Imai H; Maekawa K; Chikugo T; Kumano M; Hyodo T; Murakami T; Chiba Y; Takeyama Y
    Endoscopy; 2014 Jan; 46(1):22-9. PubMed ID: 24218310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer.
    Del Chiaro M; Verbeke CS; Kartalis N; Pozzi Mucelli R; Gustafsson P; Hansson J; Haas SL; Segersvärd R; Andren-Sandberg Å; Löhr JM
    JAMA Surg; 2015 Jun; 150(6):512-8. PubMed ID: 25853369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refinement of screening for familial pancreatic cancer.
    Bartsch DK; Slater EP; Carrato A; Ibrahim IS; Guillen-Ponce C; Vasen HF; Matthäi E; Earl J; Jendryschek FS; Figiel J; Steinkamp M; Ramaswamy A; Vázquez-Sequeiros E; Muñoz-Beltran M; Montans J; Mocci E; Bonsing BA; Wasser M; Klöppel G; Langer P; Fendrich V; Gress TM
    Gut; 2016 Aug; 65(8):1314-21. PubMed ID: 27222532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precursor Lesions of Pancreatic Cancer.
    Kim JY; Hong SM
    Oncol Res Treat; 2018; 41(10):603-610. PubMed ID: 30269131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic.
    Borecka M; Zemankova P; Vocka M; Soucek P; Soukupova J; Kleiblova P; Sevcik J; Kleibl Z; Janatova M
    Cancer Genet; 2016 May; 209(5):199-204. PubMed ID: 27106063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
    Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
    J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
    Abe T; Blackford AL; Tamura K; Ford M; McCormick P; Chuidian M; Almario JA; Borges M; Lennon AM; Shin EJ; Klein AP; Hruban RH; Canto MI; Goggins M
    J Clin Oncol; 2019 May; 37(13):1070-1080. PubMed ID: 30883245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
    Levink IJM; Klatte DCF; Hanna-Sawires RG; Vreeker GCM; Ibrahim IS; van der Burgt YEM; Overbeek KA; Koopmann BDM; Cahen DL; Fuhler GM; Wuhrer M; Bonsing BA; Tollenaar RAEM; Vleggaar FP; Vasen HFA; van Leerdam ME; Bruno MJ; Mesker WE
    Pancreatology; 2022 May; 22(4):497-506. PubMed ID: 35414481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals.
    Labiner AJ; Aronson A; Lucas AL
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):929-942. PubMed ID: 36265991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline mutations in Japanese familial pancreatic cancer patients.
    Takai E; Yachida S; Shimizu K; Furuse J; Kubo E; Ohmoto A; Suzuki M; Hruban RH; Okusaka T; Morizane C; Furukawa T
    Oncotarget; 2016 Nov; 7(45):74227-74235. PubMed ID: 27732944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress report: familial pancreatic cancer.
    Mintziras I; Bartsch DK
    Fam Cancer; 2019 Jul; 18(3):359-362. PubMed ID: 30796632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Approaches to Pancreatic Cancer Screening.
    Chhoda A; Lu L; Clerkin BM; Risch H; Farrell JJ
    Am J Pathol; 2019 Jan; 189(1):22-35. PubMed ID: 30558719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study.
    Kimura H; Ohtsuka T; Matsunaga T; Watanabe Y; Tamura K; Ideno N; Aso T; Miyazaki T; Osoegawa T; Aishima S; Miyasaka Y; Ueda J; Ushijima Y; Igarashi H; Ito T; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Oct; 44(7):1148-54. PubMed ID: 26284536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pancreatic cancer-screening or surveillance?].
    Sirtl S; Vornhülz M; Hofmann FO; Mayerle J; Beyer G
    Radiologie (Heidelb); 2023 Dec; 63(12):908-915. PubMed ID: 37878016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.